Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of biomarkers, current and emerging therapies, and how the latest clinical …
Developmental and epileptic encephalopathies (DEEs) make up a diverse range of conditions that generally present with epileptic seizures and electroencephalogram (EEG) abnormalities. DEEs significantly impact children and adults living with the condition, as well as their caregivers. Patients and caregivers …
Developmental and epileptic encephalopathies (DEEs) make up a diverse range of conditions that generally present with significant epileptic seizures and electroencephalogram (EEG) abnormalities. DEEs can significantly impact children and adults living with the condition, as well as caregivers. Patients within …
Biomarker and molecular testing to help oncologists match patients with the best cancer treatment can be challenging in the community oncology setting and in underserved communities. At present, patients with cancer in racially or ethnicly underserved communities are not receiving …
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune, neuro-muscular condition impacting the myelin that insulates and protects peripheral nerves causing mobility and sensory impairment. Standard therapies for CIPD have been recommended for decades, however, there are many unmet needs related …
Health inequities in the diagnosis, treatment, and outcomes of gastrointestinal disorders significantly impact racial, ethnic, and immigrant populations. Patients born outside the U.S. are less likely to be diagnosed with inflammatory bowel disease (IBD) before age 16 and often face …
Crohn’s disease (CD) can cause progressive bowel damage, impaired quality of life, and permanent disability. Severity and presentation can vary widely from person to person, necessitating an individualized treatment approach. The use of more readily available imaging modalities such as …
Ulcerative colitis (UC) affects around three million people in the United States. Delays in treatment coverage approval, costs of managing the disease, and uncertainties around new treatment options significantly impact how well patients react to treatment, and short- and long-term …
